Pharming Group N.V. Files 6-K with Press Release

TL;DR

Pharming Group N.V. dropped a press release today via a 6-K filing - check it for news.

AI Summary

Pharming Group N.V. filed a Form 6-K on August 1, 2024, to furnish a press release dated August 1, 2024. The filing itself does not contain detailed financial information but serves as a notification of the attached press release, which is expected to contain the substantive business updates.

Why It Matters

This filing indicates that Pharming Group N.V. is providing an important update to investors via a press release, which may contain material business or financial information.

Risk Assessment

Risk Level: low — This filing is a routine submission of a press release and does not inherently present new financial risks.

Key Players & Entities

• Pharming Group N.V. (company) — Registrant
• August 1, 2024 (date) — Press Release Date
• 001-39822 (other) — Commission File Number

FAQ

From the Filing

0001828316-24-000029.txt : 20240801 0001828316-24-000029.hdr.sgml : 20240801 20240801060710 ACCESSION NUMBER: 0001828316-24-000029 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20240801 FILED AS OF DATE: 20240801 DATE AS OF CHANGE: 20240801 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharming Group N.V. CENTRAL INDEX KEY: 0001828316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39822 FILM NUMBER: 241163977 BUSINESS ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR BUSINESS PHONE: 31 (0)71 5247 400 MAIL ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR FORMER COMPANY: FORMER CONFORMED NAME: Pharming Group Group N.V. DATE OF NAME CHANGE: 20201014 6-K 1 a2024hy1pressrelease.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2024 Commission File Number: 001-39822 Pharming Group N.V. (Exact Name of Registrant as Specified in Its Charter) Darwinweg 24 2333 CR Leiden The Netherlands (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., dated August 1, 2024. 1 EXHIBIT INDEX Exhibit No. Description 99.1 Pharming Group reports second quarter and first half 2024 financial results and provides business update SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Pharming Group N.V. By: /s/ Sijmen de Vries Name: Sijmen de Vries Title: CEO Date: August 1, 2024 2 Pharming Group reports second quarter and first half 2024 financial results and provides business update • Second quarter 2024 total revenues increased by 35% to US$74.1 million, compared to the second quarter 2023, driven by strong RUCONEST® and Joenja® revenue growth • RUCONEST® second quarter revenue increased by 23% to US$63.0 million, compared to the second quarter 2023 • Joenja® (leniolisib) second quarter revenue increased by 16% to US$11.1 million, compared to the first quarter 2024 • First half total revenues increased by 33% to US$129.7 million, compared to the first half 2023 • On track for 2024 total revenue guidance of US$280 million - US$295 million (14 - 20% growth) • Overall cash and marketable securities declined to US$161.8 million at the end of the second quarter 2024 from US$203.5 million at the end of the first quarter 2024, primarily due to convertible bond refinancing • Pharming to host a conference call today at 13:30 CEST (7:30 am EDT) Leiden, the Netherlands, August 1, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) presents its preliminary (unaudited) financial report for the second quarter and first half year ended June 30, 2024. Chief Executive Officer, Sijmen de Vries, commented: “Pharming has delivered another strong quarter of revenue growth, increasing quarterly revenues by 35% to US$74.1 million. We are firmly on track to meet our 2024 total revenue guidance of US$280 m